This report first describes how often we have come close to implementing national pharmacare and why we have fallen short. We then describe who supports – and should support – national pharmacare. We will describe who might lose from pharmacare and why these potential losers pose a continuing threat to its implementation. Finally, we will then go through how national pharmacare can be approached, in terms of governance, design and financing.